# Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

> **NCT00036088** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 530 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT00036088
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** —
- **Final completion:** 2002-07
- **Target enrollment:** 530 (—)
- **Last updated:** 2006-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00036088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00036088, "Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00036088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*